Focused on developing and commercializing antibiotics for serious bacterial infections, the company built a portfolio of hospital-targeted therapies including treatments for drug-resistant pathogens. Its products have included FDA‑approved antibiotics such as Vabomere and Baxdela, aimed at addressin...
1 member of Congress has disclosed 1 trade in Melinta Therapeutics Inc (MLNT), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-06-24 | MICHAEL T. MCCAUL | buy | $1K – $15K |